Analyst Reco. Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
33.87 ^USD	+1.20%		-4.27%	-29.33%

05-15	HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	MT
05-14	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	05-15	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	03-28	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	03-27	MT
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	02-27	MT
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	12-04	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	11-29	MT
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	11-10	MT
Baird Downgrades Frequency Therapeutics to Neutral From Outperform	26/09/23	MT
Chardan Downgrades Frequency Therapeutics to Neutral From Buy	15/02/23	MT
Baird Adjusts Frequency Therapeutics Price Target to $4 From $10, Maintains Outperform Rating	14/02/23	MT
Oppenheimer Downgrades Frequency Therapeutics to Perform From Outperform, Removes $8 Price Target	14/02/23	MT
Cowen Downgrades Frequency Therapeutics to Market Perform From Outperform	13/02/23	MT
Chardan Initiates Frequency Therapeutics With Buy Rating, $7 Price Target	08/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Korro Bio, Inc.

Equities

KRRO

US5009461089

Analyst Reco.

Filters